Initial trials of stem cell treatment for hypoplastic left heart syndrome have proven to be both safe and effective for children with the congenital defect.
Researchers from Okayama University have developed a method to treat the congenital heart defect known as hypoplastic left heart syndrome [HLHS] by utilizing a specialized cardiac stem cell. In a Phase I clinical trial conducted on children suffering from HLHS, the scientists concluded that, because the young stem cells in children are more abundant and self-renewing than those in adults, intracoronary injection of stem cells is a safe and feasible approach to treating the condition. Continue reading →
Although duchenne muscle dystrophy affects the entire body, often the cause of death for DMD patients is heart failure.
Researchers led by Eduardo Marbón of the Cedars-Sinai Heart Institute have developed a method to prolong the lives of patients with Duchenne Muscular Dystrophy [DMD] through the infusion of cardiac stem cells. The stem cells reverse the loss of cardiac muscle caused by the genetic disease, preventing heart failure that would otherwise limit a patient’s life expectancy to age 25. Continue reading →
Scientists use gold nanoparticles to improve stem cell transplants for heart disease patients.
A team of bioengineers from Tel Aviv University is currently developing a scaffold to help regenerate heart muscle through the use of autologous stem cells. The scientists, led by Dr. Tal Dvir, aim to replace damaged cardiac tissue in heart attack patients by creating a scaffold out of collagen and gold nanoparticles, and then infusing it with the patient’s own stem cells to stimulate the rejuvenation of cardiomyocytes. Continue reading →
Columbia researchers have developed a scaffold that will allow stem cells to repair heart damage.
A team of researchers led by Dr. Gordana Vunjak-Novakovic [a member of StemSave’s Scientific Advisory Council has engineered a scaffold to facilitate the regeneration of heart muscle through the use of adult stem cells. In an animal model, Vunjak-Novakovic and her team created a scaffold using biodegradable chitosan and carbon nanofibers, infusing it with stem cells to provoke the regeneration of beating cardiomyocytes. Continue reading →
Cell-Kro has the potential to rebuild damaged portions of the heart using the patient’s own stem cells.
Researchers from the University of Vermont have developed a novel and effective application of mesenchymal stem cells [the same type found in Dental Stem Cells] to treat heart disease. The MSCs, when transplanted along with cardiac stem cells into the heart [in an animal model], produced a “cocktail” of protective ligands that improved the grafting success of the cardiac stem cells. Continue reading →
The CRF will discussed how stem cells are being used to treat cardiovascular disease
The Cardiovascular Research Foundation will be hosting the Ninth International Conference on Cell Therapy for Cardiovascular Disease from January 22nd to 24th, 2014. The conference will cover major preclinical and clinical studies, as well as the promising stem cell-based products and therapies being developed to treat cardiovascular disease. Continue reading →
Mayo Clinic Researchers have used autologous stem cells to treat heart disease
Mayo Clinic researchers from the Center of Regenerative Medicine have utilized a patient’s own stem cells in a novel treatment for heart disease. The treatment involves harvesting the patient’s own stem cells, expanding and differentiating them in-vitro [outside the body] and transplanting them back into the patient. As a result of the successful initial study, a wider clinical trial is planned.
Researchers at the University of Toronto, led by Milica Radisic, Canada Research Chair in Functional Cardiovascular Tissue Engineering and Associate Professor at the Institute of Biomaterials & Biomedical Engineering (IBBME) and the Department of Chemical Engineering, have developed a multidisciplinary technique for maturing human heart cells. The new technique, referred to as “biowire,” enables scientists to differentiate stem cells into beating cardiomyocites in vitro [outside the body]. Researchers envision utilizing the technique to create cardiac patches for transplantation to replace damaged tissue for those suffering from heart failure. Heart disease is the leading cause of death in the United States.
Hypoxic-Ischemic brain injury can be caused by a number of ailments including cardiac arrest (heart attack), respiratory arrest, incomplete suffocation and more. The incidence in the United States of hypoxic-ischemic brain injuries is 1-8 in every 1000 births. Researchers at Nagoya University have used stem cells from human exfoliated deciduous teeth (SHED) to treat neonatal mice with hypoxic-ischemic brain injuries. They have found that this treatment leads to neurological and pathophysiological recovery of these injuries. These finding indicate that SHED may be utilized in the future for a novel neuroprotective therapy for hypoxic-ischemic brain injuries. Continue reading →
Mesoblast, a leading stem cell technology and regenerative therapeutics company, received FDA approval to begin a Phase III clinical trial utilizing their stem cell therapy [Revascor] to treat heart failure. We have reported on Mesoblast in previous posts; most recently, the announcement that they were developing neural related regenerative therapies utilizing dental pulp stem cells.